The Immune Response Corporation Granted Patent in South Africa for Novel Formulation of REMUNE(R)

Vaccine Formulation Using REMUNE(R) and Immunostimulatory Sequence

Aimed at Preventive Applications

Dec 19, 2002, 00:00 ET from The Immune Response Corporation

    CARLSBAD, Calif., Dec. 19 /PRNewswire-FirstCall/ --
 The Immune Response Corporation (Nasdaq:   IMNR) announced today it has been
 granted Republic of South Africa Patent Number 2001/8559 entitled "HIV
 Immunogenic Compositions and Methods" for its latest vaccine development
 utilizing a novel formulation of REMUNE(R) in concert with immunostimulatory
 sequence aimed specifically at preventing initial HIV infections.
     "Receipt of this patent in one of the regions of the world most devastated
 by the AIDS epidemic gives us a base to further develop our core HIV vaccine,"
 said Dr. Ronald B. Moss, president of The Immune Response Corporation.
 "Studies to date using this vaccine formulation have yielded early results in
 the ability to stimulate an HIV-specific immune response in HIV-negative
     According to Dr. Moss, the patent awarded by South Africa is for a novel
 formulation whereby whole killed HIV-1 is stripped of its outer protein
 envelope and immunostimulatory sequences are added along with an adjuvant.
 This formulation process differs from that of REMUNE(R) and allows for a
 broader presentation in stimulating an immune response in HIV-negative
 subjects.  The patent term is for 20 years from the international filing date
 or until the year 2020.
     The Company previously released study results by the Southern Research
 Institute in collaboration with The National Institutes of Health and the
 Jonas Salk Foundation, which utilized this vaccine formulation to stimulate
 HIV-specific immune responses, resulting in the boosting of both antibody and
 cell mediated immunity in Rhesus macaques.
     "Our goal with this vaccine formulation was to induce HIV-specific
 immunity as an approach for use as a preventive vaccine," Dr. Moss said.  "Our
 initial results in animal studies led us to begin working in this area in
 terms of intellectual property protection and seeking partners to further
 develop on our early clinical work."
     The Company also has submitted this vaccine formulation for patent
 protection in other parts of the world, including the U.S. and Europe, and is
 seeking appropriate partners to further develop this approach, Dr. Moss said.
     According to recent reports from the U.S. Agency for International
 Development, over 4.2 million South Africans are infected with HIV/AIDS, or
 approximately 20 percent of the population.  The agency estimates that one of
 every 10 new HIV/AIDS infections in the world occurs in South Africa, giving
 it the highest documented infection rate in the world.  The current prevalence
 rate among adults is almost 23 percent (in 1992, it was roughly two percent).
     Co-founded by medical pioneer Dr. Jonas Salk and based in Carlsbad,
 Calif., The Immune Response Corporation is a biopharmaceutical company
 developing immune-based therapies designed to treat HIV, autoimmune diseases
 and cancer.  The Company also develops and holds patents on several
 technologies that can be applied to genes in order to increase gene expression
 or effectiveness, making it useful in a wide range of therapeutic applications
 for a variety of disorders.  Company information is available at .
     This news release contains forward-looking statements.  Actual results
 could vary materially from those expected due to a variety of risk factors,
 including, but not limited to, whether the Company will successfully raise
 proceeds from financing activities sufficient to fund additional trials and
 development of REMUNE(R) in South Africa, the United States, Europe or
 elsewhere, whether any such clinical trials will be successful in meeting
 their primary endpoints and whether the Company will be successful in
 commercializing REMUNE(R) in South Africa, the United States, Europe or in any
 other jurisdiction.  These and other risk factors are discussed more
 thoroughly in The Immune Response Corporation's SEC filings, including but not
 limited to its report on Form 10-K for the year ended December 31, 2001 and
 report on Form 10-Q for the quarter ended September 30, 2002.  The Company
 undertakes no obligation to publicly release the result of any revisions to
 these forward-looking statements, which may be made to reflect events or
 circumstances after the date hereof or to reflect the occurrence of
 unanticipated events.
                      MAKE YOUR OPINION COUNT - Click Here

SOURCE The Immune Response Corporation